TC Biopharm () Statistics Share Statistics TC Biopharm () has 512.99K
shares outstanding. The number of shares has increased by 156.91%
in one year.
Shares Outstanding 512.99K Shares Change (YoY) 156.91% Shares Change (QoQ) 1554.19% Owned by Institutions (%) 0.22% Shares Floating 2.47K Failed to Deliver (FTD) Shares 5,831 FTD / Avg. Volume 1.54%
Short Selling Information Short Interest n/a Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) n/a
Valuation Ratios The PE ratio is -41.71 and the forward
PE ratio is null.
TC Biopharm ()'s PEG ratio is
0.83.
PE Ratio -41.71 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 91.76 P/FCF Ratio -23.12 PEG Ratio 0.83
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for TC Biopharm ().
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 1.2,
with a Debt / Equity ratio of 0.67.
Current Ratio 1.2 Quick Ratio 1.2 Debt / Equity 0.67 Debt / EBITDA -0.13 Debt / FCF -0.17 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-144.07K Employee Count 41 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -1.09M Effective Tax Rate 15.56%
Stock Price Statistics The stock price has increased by -99.79% in the
last 52 weeks. The beta is 0.01, so TC Biopharm ()'s
price volatility has been higher than the market average.
Beta 0.01 52-Week Price Change -99.79% 50-Day Moving Average 1.52 200-Day Moving Average 43.03 Relative Strength Index (RSI) 39.17 Average Volume (20 Days) 377,721
Income Statement
Revenue n/a Gross Profit n/a Operating Income -14.24M Net Income -5.91M EBITDA -13.61M EBIT n/a Earnings Per Share (EPS) -0.05
Full Income Statement Balance Sheet The company has 2.46M in cash and 1.8M in
debt, giving a net cash position of 661.45K.
Cash & Cash Equivalents 2.46M Total Debt 1.8M Net Cash 661.45K Retained Earnings -38.84M Total Assets 6.87M Working Capital 423.86K
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -10.54M
and capital expenditures -110.35K, giving a free cash flow of -10.66M.
Operating Cash Flow -10.54M Capital Expenditures -110.35K Free Cash Flow -10.66M FCF Per Share -0.09
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields TCBP does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for TCBP is $48,
which is 9500% higher than the current price. The consensus rating is "Buy".
Price Target $48 Price Target Difference 9500% Analyst Consensus Buy Analyst Count 1
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Feb 10, 2025. It was a
backward
split with a ratio of 1:20.
Last Split Date Feb 10, 2025 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -14.71 Piotroski F-Score 2
